1007223-17-7
1007223-17-7
Chemical Structure
Olokizumab
Synonym(s): CDP 6038; OKZ
- CAS No.: 1007223-17-7
- Formula:N/A
- Molecular Weight:(145.94 kDa)
SMILES: [Olokizumab]
Biological Activity: Olokizumab (CDP 6038) is a humanized monoclonal antibody that targets interleukin-6 (IL-6). Olokizumab inhibits IL-6-induced STAT-3 phosphorylation. Olokizumab is used in the study of arthritis[1][2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Olokizumab | 99.54% | Olokizumab (CDP 6038) is a humanized monoclonal antibody that targets interleukin-6 (IL-6). Olokizumab inhibits IL-6-induced STAT-3 phosphorylation. Olokizumab is used in the study of arthritis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Kretsos K, et, al. Model-Based Optimal Design and Execution of the First-Inpatient Trial of the Anti-IL-6, Olokizumab. CPT Pharmacometrics Syst Pharmacol. 2014 Jun 18;3(6):e119. [Content Brief]
- [2]. Shaw S, et al. Discovery and characterization of olokizumab: a humanized antibody targeting interleukin-6 and neutralizing gp130-signaling. MAbs. 2014 May-Jun;6(3):774-82. [Content Brief]
- [3]. Tavakolpour S. Anti-interleukin and associated receptors monoclonal antibodies therapy in autoimmune diseases. Receptors & Clinical Investigation, 2016, 3.
Keywords
